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Puzzles in the causation and epidemiology of prostate
cancer — a sombre outlook
Prostate cancer was apparently rare in the past, although
reliable knowledge is very limited. Thus, for example,
according to a 1918 report by the Medical Officer of Health, in
Woolwich, London,1 not one of 238 cancer patients admitted to
the local hospital was found to have cancer of the prostate
gland. Also in  early times, both in the UK and in the USA, the
proportion of cancers actually verified were minute. Thus, in a
1914 report by the US Bureau of Census2 concerning a
document claimed to be ‘the most careful statistical study of
cancer in the US which has ever been made’, it was admitted
that in ‘an examination of about 2 000 death certificates from
an estimated 50 000 deaths from cancer, it was found that in
only 2% of the cases was the diagnosis confirmed by autopsy,
and in only another 9% had an operation confirmed the clinical
diagnosis’.
At present, prostate cancer is a very common malignancy in
many countries. In the USA it accounts for almost one-third
(31.2%) of all cancers, ranking second only to lung cancer as
the underlying cause of death in men (11.7%).3
In 2000, the respective age standardised incidence rates for
prostate cancer were very high in the US African American and
white populations, namely 222.9 and 147.3 per 100 000.4 The
high rate for African American men, believed to have a
measure of racial significance, is thought to be the highest in
the world.5 A point of major epidemiological importance
concerns the differences in rates, as much as 90-fold, between
populations.6 For example, for the years 1993 - 1995 the
standardised incidence rate in the American white population
in Detroit was 108.2, almost double the rate in Louisiana of
64.8/100 000. Among African Americans the corresponding
rates in the two cities were 141.5 and 80.2/100 000, respectively.
Major regional differences also prevail in occurrence of the
disease within some European countries, e.g. in 1993 - 1995 the
rate in Raguza, Italy was 12.0, but in Trieste it was far higher at
48.8/100 000.7
Recent estimates of incidence rates vary enormously among
black African populations. In the Gambia the rate in 1988 - 1997
was very low at 1.2/100 000.8 It was subsequently found to be
higher in Mali (6.3/100 000).7 In South Africa the rate was
(13.0/100 000),9 but it was very much higher in Harare,
Zimbabwe, at 29.2/100 000,7 in Abidjan, Ivory Coast at
31.4/100 000,10 and Kyadondo, Uganda at 39.2/100 000,7
elevated rates that are difficult to explain. In comparison, in
Europe the incidence rate in the UK was 28.0/100 000, while in
Sweden it was higher at 55.3/100 000.7 In making comparisons
an important point to bear in mind with regard to developed
and developing populations is the far higher rate of total
cancers in whites compared with African populations. Thus in
1993 - 1995 the total rates in the UK and Sweden were 303 and
252/100 000 respectively,7 whereas among black Africans in
South Africa9 and in Abidjan, Ivory Coast10 rates were 93.9 and
87.5/100 000, respectively.
The proportion of cancer patients with prostate cancer in the
UK and Sweden was found to be 12.0% and 10.5%,
respectively.7 Among black Africans in South Africa the
proportion was 10.3%,8 while in Abidjan it was higher at
15.3%.10
In series of prostate cancer patients in Canada and Sweden
mean age at the time of diagnosis was reported to be 69.7 and
70.5 years, respectively.11,12 In China the average age was 65
years,13 while in Nairobi, East Africa14 and Abidjan,10 patients
averaged 67.5 and 68.5 years, respectively. The mean ages of
patients in the various settings are therefore roughly similar,
despite the far younger age of African populations. Life
expectancy in the latter African populations is not known. In
1987 life expectancy of South African blacks was 62 years.15
Unfortunately, as with many other African populations, this
figure has been greatly reduced by the advent of HIV/AIDS to
40 - 45 years.16,17 In comparison life expectancy of white males
in the UK and Sweden has been reported to be 75 and 72 years,
respectively.18
With regard to the causation of prostate cancer, a recent
major review19 on the aetiology and occurrence of the disease
greatly regretted that ‘little specific insight has been gained into
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identifying the aetiological factors, or the mechanisms
involved’. It was stressed that almost 10-fold differences in the
incidence and mortality rates for prostate cancer prevail
between various geographical and ethnic populations. Apart
from evidence of a familial component,20 it was stated that
‘although several dietary and lifestyle risk factors have been
linked to the disease, there is still no consensus that these risk
factors truly influence tumour development’.21 There has been
recent confirmation regarding how little is known about what
causes the disease.22
With regard to the possibility of reducing morbidity/
mortality by screening, a recent survey concluded that ‘no
conclusive direct evidence shows that screening reduces
prostate cancer mortality’.21 Furthermore, sadly, it has been
stated that ‘men with an expectancy of fewer than 10 years are
unlikely to benefit from screening even under favourable
conditions. Each treatment is associated with well-documented
potential harms.’22
Here then, is a highly adverse epidemiological situation —
malignancy of the prostate gland still virtually absent in
numerous black African populations, particularly among rural
dwellers, while at the other extreme African American men
have the highest rate in the world.
With regard to causation, some evidence suggests that
prostate cancer is associated with a high intake of fat, meat,
and dairy produce.6 Other factors such as smoking, alcohol
consumption, vasectomy and physical activity have been
investigated, but the overall conclusion is that they do not
affect the risk of prostate cancer.6
While lack of information on the cause and development of
prostate cancer is very disappointing, a crucial question is
whether if more information were available it would be
adopted and practised sufficiently, through significant lifestyle
change to avoid the disease. Unfortunately, the answer seems
negative. In the USA and doubtless in other developed
countries there is a high level of knowledge of general health
needs, but in the case of most individuals healthy changes in
behaviour are not sustained. For example, the US population is
now deemed ‘the fattest nation in the world’.23 Yet in that
country the cost of the treatment of overweight and obesity
was estimated to have been US$117 billion in 2000, nearly 10%
of the US health care expenditure.24 Furthermore,
notwithstanding the well-known health benefits of physical
exercise it has been reported that only 15% of adults now
engage in regular vigorous physical activity, while 60% report
no regular or sustained leisuretime exertion.25 The rate of
smoking has fallen among adult men; however, in 2000, 23.3%
of men were still smokers,26 and smoking frequency is rising
among the young.27 In brief, even were practicable preventive
information to become available on the possible avoidance of
prostate cancer, the likelihood of the requisite measures being
significantly applied, in the long term, is remote. Accordingly, a
worsening situation with regard to prostate cancer occurrence
seems inevitable in the USA, doubtless in other developed
countries, and among urban dwellers in certain developing
countries.
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